Filamon Limited

Filamon sees itself as a drug discoverer and drug developer for major pharma. Filamon is a public, clinical stage, Australian biotechnology company focused on the development of novel treatments for age-related diseases. Diseases being targeted are inflammation associated with cancer, the eye (wet AMD) and the brain (Alzheimer’s Disease). A feature of the Filamon drug pipeline is molecules singling out drug targets previously considered to be undruggable because of major safety concerns. Those concerns have led the pharmaceutical industry to a focus on peripheral targets that are safer to inhibit but also less effective as drug targets. Filamon drug candidates are designed to safely drug those targets previously considered off-limits, offering the prospect of major progress in the treatment of major degenerative and inflammatory diseases. The Company’s Board and Management have decades-long experience in drug and clinical development and corporate management.